Patent intelligence · US
US 11542290
Phenothiazine derivatives and uses thereof
Phenothiazine derivatives and uses thereof
Patent details — US 11542290
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 3, 2023
- Expiration
- Dec 29, 2042
- Applicant
- CAMP4 Therapeutics Corporation
- Claims
- 6
- CPC classes
- A61P, A61P1/00, A61P1/12, A61P25/28
Quick answer
US 11542290 (Phenothiazine derivatives and uses thereof) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Jan 3, 2023. Expires Dec 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAMP4 Therapeutics Corporation
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61P, A61P1/00, A61P1/12, A61P25/28, A61P43/00, A61P7/06
More from CAMP4 Therapeutics Corporation
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11542290?
US 11542290 (Phenothiazine derivatives and uses thereof) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Jan 3, 2023. Expires Dec 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11542290?
CAMP4 Therapeutics Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11542290 expire?
Our index shows an expiration date of Dec 29, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.